Date:3/17/2009

------------ -------- -------- 162,865 (1,343) 41,144 ------------ -------- -------- Foreign exchange gain (loss) on cash and cash equivalents held in foreign currency 2,849 3,698 (849) ------------ -------- -------- Increase (decrease) in cash and cash equivalents 87,826 52,398 (1,988) Cash and cash equivalents - Beginning of period - 35,428 37,416 ------------ -------- -------- Cash and cash equivalents - End of period 87,826 87,826 35,428 ------------ -------- -------- ------------ -------- -------- Cash and cash equivalents consists of Bank accounts 610 610 1,139 Interest bearing deposits and securities 87,216 87,216 34,289 ------------ -------- -------- 87,826 87,826 35,428 ------------ -------- -------- ------------ -------- --------

'/>"/>

SOURCE BioMS Medical Corp. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference